FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileFranklin Genomic Advancements ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
HELX
Franklin Genomic Advancements ETF ETF AnalysisComprehensive ETF analysis for Franklin Genomic Advancements ETF (HELX) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisHELX
HELX
Franklin Genomic Advancements ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
HELX
  1. Home
  2. Screener
  3. Franklin Genomic Advancements ETFHELXETF
Franklin Genomic Advancements ETF Logo

Franklin Genomic Advancements ETF

ETF
🇺🇸HELX•CBOE•Equity

Your view on HELX

Franklin Genomic Advancements ETF Logo

Franklin Genomic Advancements ETF

ETFFranklin Templeton
🇺🇸HELX•CBOE•Equity
AUM (USD)$32.94M
Expense Ratio0.5%
Yield (TTM)0.35%
Holdings63

Sentiment

—

AUM (USD)

$32.94M

Expense Ratio

0.5%

Yield (TTM)

0.35%

Holdings

63

Sentiment

—
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

Franklin Genomic Advancements ETF (HELX) is an Equity fund from Franklin Templeton, listed since 2020, with $32.9M in assets under management, a 0.50% expense ratio and a NAV of $41.17 USD.

Overview for Franklin Genomic Advancements ETF

Fund Type
ETF
Fund Issuer
Franklin Templeton
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
February 25, 2020
Domicile
US
Website
franklintempleton.com/investments/options/exchange-traded-funds/products/29097/SINGLCLASS/franklin-genomic-advancements-etf/HELX
Fund Type
ETF
Fund Issuer
Franklin Templeton
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
February 25, 2020
Domicile
US
Website
franklintempleton.com/investments/options/exchange-traded-funds/products/29097/SINGLCLASS/franklin-genomic-advancements-etf/HELX
Fund Type
ETF
Fund Issuer
Franklin Templeton
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
February 25, 2020
Domicile
US
Website
franklintempleton.com/investments/options/exchange-traded-funds/products/29097/SINGLCLASS/franklin-genomic-advancements-etf/HELX

About this fund

This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emergin…

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Equity

Expense Ratio

0.5%

Yield (TTM)

0.35%

AUM

$32.94M

Fund Details

NAV$41.17 USD
Holdings63
Average Volume5.0K
Inception DateFebruary 25, 2020
Asset ClassEquity
Fund IssuerFranklin Templeton
DomicileUS
ISINUS35473P5200
CUSIP35473P520
NAV CurrencyUSD

Expense Ratio

0.5%

Dividend Yield (TTM)

0.35%

Assets Under Management

$32.94M

NAV

$41.17 USD

Holdings

63

Average Volume

5.0K

Inception Date

February 25, 2020

Asset Class

Equity

Fund Issuer

Franklin Templeton

Domicile

US

ISIN

US35473P5200

CUSIP

35473P520

NAV Currency

USD

Expense Ratio

0.5%

Dividend Yield (TTM)

0.35%

Assets Under Management

$32.94M

NAV

$41.17 USD

Holdings

63

Average Volume

5.0K

Inception Date

February 25, 2020

Asset Class

Equity

Fund Issuer

Franklin Templeton

Domicile

US

ISIN

US35473P5200

CUSIP

35473P520

NAV Currency

USD

Distributions · last 12 months

Irregular · 1 payment

Ex-datePaidAmount
Dec 30, 2025Jan 8, 2026$0.1433
Total, 12 months$0.14 a share

Dividend yield (TTM) 0.35% = $0.14 paid per share in the 12 months to Nov 20, 2026 ÷ the $41.33 price. Past distributions; future payments can differ.

Data last updated: Nov 18, 2026, 08:11 AM

Sectors

How the fund's assets are split across sectors.

4 sectors
  • 1Healthcare
    96.8%
  • 2Financial Services
    2.2%
  • 3Technology
    0.7%
  • 4Basic Materials
    0.3%

Top sector

Healthcare

Top weight

96.8%

Top 3 weight

99.7%

Holdings

The securities the fund owns, by weight.

70 positions
1GHGUARDANT HEALTH INC
8.63%
2NTRANATERA INC
7.79%
3KRYSKRYSTAL BIOTECH INC
5.26%
4ADPTADAPTIVE BIOTECHNOLOGIES
5.10%
5LGNDLIGAND PHARMACEUTICALS
4.47%
6BBIOBRIDGEBIO PHARMA INC
3.59%
7TWSTTWIST BIOSCIENCE CORP
3.31%
8MEDPMEDPACE HOLDINGS INC
2.93%
9LLYELI LILLY & CO
2.83%
10VRTXVERTEX PHARMACEUTICALS IN
2.81%
11UTHRUNITED THERAPEUTICS CORP
2.80%
12REGNREGENERON PHARMACEUTICALS
2.60%
13TVTXTRAVERE THERAPEUTICS INC
2.39%
14VYLRVYLOR INC
2.17%
15CDNACAREDX INC
2.01%

Concentration

Total Holdings70
Top 10 Weight46.73%
Top HoldingGH
Top Weight8.63%
1GHGUARDANT HEALTH INC
8.63%
2NTRANATERA INC
7.79%
3KRYSKRYSTAL BIOTECH INC
5.26%
4ADPTADAPTIVE BIOTECHNOLOGIES
5.10%
5LGNDLIGAND PHARMACEUTICALS
4.47%
6BBIOBRIDGEBIO PHARMA INC
3.59%
7TWSTTWIST BIOSCIENCE CORP
3.31%
8MEDPMEDPACE HOLDINGS INC
2.93%
9LLYELI LILLY & CO
2.83%
10VRTXVERTEX PHARMACEUTICALS IN
2.81%
11UTHRUNITED THERAPEUTICS CORP
2.80%
12REGNREGENERON PHARMACEUTICALS
2.60%
13TVTXTRAVERE THERAPEUTICS INC
2.39%
14VYLRVYLOR INC
2.17%
15CDNACAREDX INC
2.01%

Total Holdings

70

Top 10 Weight

46.73%

Top Holding

GH

Top Weight

8.63%

1GHGUARDANT HEALTH INC
8.63%$2.82M
2NTRANATERA INC
7.79%$2.54M
3KRYSKRYSTAL BIOTECH INC
5.26%$1.72M
4ADPTADAPTIVE BIOTECHNOLOGIES
5.10%$1.67M
5LGNDLIGAND PHARMACEUTICALS
4.47%$1.46M
6BBIOBRIDGEBIO PHARMA INC
3.59%$1.17M
7TWSTTWIST BIOSCIENCE CORP
3.31%$1.08M
8MEDPMEDPACE HOLDINGS INC
2.93%$956.7K
9LLYELI LILLY & CO
2.83%$925.5K
10VRTXVERTEX PHARMACEUTICALS IN
2.81%$919.0K
11UTHRUNITED THERAPEUTICS CORP
2.80%$913.6K
12REGNREGENERON PHARMACEUTICALS
2.60%$847.7K
13TVTXTRAVERE THERAPEUTICS INC
2.39%$780.7K
14VYLRVYLOR INC
2.17%$708.4K
15CDNACAREDX INC
2.01%$657.5K

Total Holdings

70

Top 10 Weight

46.73%

Top Holding

GH

Top Weight

8.63%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on20 funds
FundAsset classExpense ratioAssetsHoldings
HELXFranklin Genomic Advancements ETFThis fundEquity0.50%$33M63

Comparable funds

  • BWTGBrendan Wood TopGun ETFEquity0.98%$20M22
  • BYREPrincipal Real Estate Active Opportunities ETFEquity0.60%$28M48
  • DGINVanEck Digital India ETFEquity0.70%$12M31
  • FMKTFree Markets ETFEquity0.75%$10M0
  • MEDXHorizon Kinetics Medical ETFEquity0.85%$18M32
  • QRMIGlobal X - Nasdaq 100 Risk Managed Income ETFEquity0.60%$15M105
  • RHRXRH Tactical Rotation ETFEquity1.38%$59M7
  • RWRainwater Equity ETFEquity0.95%$17M0

More Franklin Templeton ETFs

  • FLVC.NEFranklin Canadian Low Volatility High Dividend Index ETFEquity0.18%$32M0
  • FRIZFranklin Dividend Growth ETFEquity0.49%$130M0
  • FSMLFranklin Small Cap Enhanced ETFEquity0.45%$146M0
  • FTCAFranklin California Municipal Income ETFFixed Income0.35%$763M301
  • FTMHFranklin Municipal High Yield ETFFixed Income0.35%$719M522
  • FTMSFranklin Short-Term Municipal Income ETFFixed Income0.22%$266M286
  • FTMUFranklin Municipal Income ETFFixed Income0.30%$498M267
  • FTNJFranklin New Jersey Municipal IFixed Income0.36%$201M165
  • FTNYFranklin New York Municipal Income ETFFixed Income0.37%$604M263
  • FTPAFranklin Pennsylvania Municipal Income ETFFixed Income0.36%$126M134
  • FTSDFranklin Short Duration U.S. Government ETFFixed Income0.25%$370M4
  • INCEFranklin Income Equity Focus ETFEquity0.29%$370M113
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.

News

Latest Market News

News

Latest Market News